{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:28Z","timestamp":1791646468640,"version":"4.3.4"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for treating chronic inflammatory diseases. Modulation of systemic and airway inflammation is their pivotal mechanism of action. Furthermore, PDE inhibitors modulate cough reflex and inhibit airway mucus secretion. Roflumilast, a selective PDE4 inhibitor, has been extensively studied for the efficacy and safety in chronic obstructive pulmonary disease (COPD) patients. According to the mechanisms of action, the potential roles of PDE inhibitors in treating chronic respiratory diseases including severe asthma, asthma-COPD overlap (ACO), noncystic fibrosis bronchiectasis, and chronic cough are discussed. Since roflumilast inhibits airway eosinophilia and neutrophilia in COPD patients, it reduces COPD exacerbations in the presence of chronic bronchitis in addition to baseline therapies. The clinical studies in asthma patients have shown the comparable efficacy of roflumilast to inhaled corticosteroids for improving lung function. However, the clinical trials of roflumilast in severe asthma have been limited. Although ACO is common and is also associated with poor outcomes, there is no clinical trial regarding its efficacy in patients with ACO despite a promising role in reducing COPD exacerbation. Since mucus hypersecretion is a result of neutrophil secretagogue in patients with chronic bronchitis, experimental studies have shown that PDE4s are regulators of the cystic fibrosis transmembrane conductance regulator (CFTR) in human airway epithelial cells. Besides, goblet cell hyperplasia is associated with an increased expression of PDE. Bronchiectasis and chronic bronchitis are considered neutrophilic airway diseases presenting with mucus hypersecretion. They commonly coexist and thus lead to severe disease. The role of roflumilast in noncystic fibrosis bronchiectasis is under investigation in clinical trials. Lastly, PDE inhibitors have been shown modulating cough from bronchodilation, suppressing transient receptors potential (TRP), and anti-inflammatory properties. Hence, there is the potential role of the drug in the management of unexplained cough. However, clinical trials for examining its antitussive efficacy are pivotal. In conclusion, selective PDE4 inhibitors may be potential treatment options for chronic respiratory diseases apart from COPD due to their promising mechanisms of action.<\/jats:p>","DOI":"10.3389\/fphar.2021.518345","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:29:08Z","timestamp":1628144948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Theerasuk","family":"Kawamatawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bcpt.12209","article-title":"Dual PDE3\/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases","volume":"114","author":"Abbott\u2010Banner","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1801219","DOI":"10.1183\/13993003.01219-2018","article-title":"Inhaled corticosteroids in COPD: friend or foe?","volume":"52","author":"Agusti","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B3","first-page":"2680","article-title":"Evaluation of patients with nasal polyps about the possible association of desmosomal junctions, RORA and PDE4D gene","volume":"17","author":"Apuhan","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"692352","DOI":"10.1155\/2012\/692352","article-title":"Macrolide therapy in chronic inflammatory diseases","volume":"2012","author":"Asano","year":"2012","journal-title":"Mediators Inflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2015.08.006","article-title":"Roflumilast for asthma: efficacy findings in mechanism of action studies","volume":"35","author":"Bardin","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/nejm200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2015.10.002","article-title":"Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies","volume":"35","author":"Bateman","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2015.11.035","article-title":"Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma","volume":"138","author":"Bateman","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1164\/rccm.201301-0021pp","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Beghe","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bja\/aeu048","article-title":"Emergency treatment of status asthmaticus with enoximone","volume":"112","author":"Beute","year":"2014","journal-title":"Br. J Anaesth."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e94888","DOI":"10.1172\/jci.insight.94888","article-title":"A pathophysiological role of PDE3 in allergic airway inflammation","volume":"25","author":"Beute","year":"2018","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.74309","article-title":"Phosphodiesterase 3 and 4 inhibition: facing a bright future in asthma control","volume-title":"Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype","author":"Beute","year":"2018"},{"key":"B14","doi-asserted-by":"publisher","first-page":"PA2151","DOI":"10.1183\/13993003.congress-2015.PA215110.2147\/copd.s1761","article-title":"Enoximone as emergency medication for life threatening asthma and suppression of allergic airway inflammation as measured in a house dust mite asthma model","volume":"46","author":"Beute","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pupt.2017.06.009","article-title":"Cough and airway disease: the role of ion channels","volume":"47","author":"Bonvini","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2006.02.045","article-title":"Are phosphodiesterase 4 inhibitors just more theophylline?","volume":"117","author":"Boswell-Smith","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1398-9995.2005.00931.x","article-title":"Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma","volume":"61","author":"Bousquet","year":"2006","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (aria) 2008 update (in collaboration with the world health organization, GA(2)len and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e74640","DOI":"10.1371\/journal.pone.0074640","article-title":"Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-\u03b1 and chemokine production by human lung parenchyma","volume":"8","author":"Buenestado","year":"2013","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/copd.s130790","article-title":"Sarcopenia correlates with systemic inflammation in COPD","volume":"12","author":"Byun","year":"2017","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1164\/rccm.200610-1563oc","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/nejmoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0385-8146(98)00010-8","article-title":"The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro","volume":"25","author":"Cervin","year":"1998","journal-title":"Auris Nasus Larynx"},{"key":"B26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/s2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1164\/rccm.201803-0405oc","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"CD002309","DOI":"10.1002\/14651858.CD002309.pub5","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","volume":"9","author":"Chong","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B29","first-page":"6","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. Respir. J. Suppl."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1378\/chest.128.4.2954","article-title":"Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?","volume":"128","author":"Currie","year":"2005","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.cir.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1183\/09031936.00011714","article-title":"The effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients","volume":"44","author":"De Backer","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"14771","DOI":"10.1073\/pnas.0506489102","article-title":"A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis","volume":"11","author":"Ding","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"CD003137","DOI":"10.1002\/14651858.CD003137.pub2","article-title":"Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma","volume":"4","author":"Ducharme","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1165\/rcmb.2018-0065oc","article-title":"Direct inhibitory effect of the PDE4 inhibitor roflumilast on neutrophil migration in chronic obstructive pulmonary disease","volume":"60","author":"Dunne","year":"2019","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/sj.bjp.0705892","article-title":"Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils","volume":"142","author":"Eskandari","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s0140-6736(09)61252-6","article-title":"M2-127 and M2-128 study groups et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cellsig.2013.12.003","article-title":"Structural basis for the design of selective phosphodiesterase 4B inhibitors","volume":"26","author":"Fox","year":"2014","journal-title":"Cell. Signal."},{"key":"B39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/10408369991239213","article-title":"Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action","volume":"36","author":"Francis","year":"1999","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1164\/ajrccm.151.1.7812559","article-title":"Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo","volume":"151","author":"Fujimura","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e105220","DOI":"10.1371\/journal.pone.0105220","article-title":"Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease","volume":"9","author":"Garc\u00eda-Rio","year":"2014","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1465-9921-12-140","article-title":"Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects","volume":"12","author":"Gauvreau","year":"2011","journal-title":"Respir. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/jaa.s81541","article-title":"United airway disease: current perspectives","volume":"11","author":"Giavina-Bianchi","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12703\/p7-16","article-title":"Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases","volume":"7","author":"Giembycz","year":"2015","journal-title":"F1000Prime Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.celrep.2016.07.037","article-title":"A distinct lung-interstitium-resident memory CD8(+) T cell subset confers enhanced protection to lower respiratory tract infection","volume":"16","author":"Gilchuk","year":"2016","journal-title":"Cell Rep."},{"key":"B46","unstructured":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2019"},{"key":"B47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/1393003.congress-2017.pa3727","article-title":"Prevalence and characteristics of pulmonary hypertension associated with COPD - a pilot study in patients referred to a pulmonary rehabilitation program clinic","volume":"8","author":"Gologanu","year":"2013","journal-title":"Maedica (Buchar)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.pupt.2013.02.007","article-title":"Pre-clinical studies in cough research: role of Transient Receptor Potential (TRP) channels","volume":"26","author":"Grace","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1476-5381.2009.00458.x","article-title":"The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function","volume":"159","author":"Grandoch","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1183\/09031936.00119712","article-title":"Sinonasal inflammation in COPD: a systematic review","volume":"42","author":"H\u00e5kansson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/copd.s1761","article-title":"ABCD of the phosphodiesterase family: interaction and differential activity in COPD","volume":"3","author":"Halpin","year":"2008","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B54","first-page":"267","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in Vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11882-010-0107-1","article-title":"United airway disease: current perspectives","volume":"10","author":"Hellings","year":"2010","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/2013.jamaoto.342","article-title":"Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study","volume":"138","author":"Henkin","year":"2012","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"B57","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccc.2008.02.005","article-title":"The overlap syndrome: chronic obstructive pulmonary disease and obstructive sleep apnea","volume":"24","author":"Hiestand","year":"2008","journal-title":"Crit. Care Clin."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3389\/fphar.2020.01135","article-title":"Phosphodiesterase 4 inhibitors in allergic rhinitis\/rhinosinusitis","volume":"11","author":"Janosova","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1067\/mai.2002.129430","article-title":"Effects of \u03b22-agonists on resident and infiltrating inflammatory cells","volume":"15","author":"Johnson","year":"2002","journal-title":"J. Allergy. Clin. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2020.00609","article-title":"Respiratory cilia as a therapeutic target of phosphodiesterase inhibitors","volume":"6","author":"Joskova","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/copd.s5102","article-title":"Update on pulmonary hypertension complicating chronic obstructive pulmonary disease","volume":"4","author":"Jyothula","year":"2009","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.21037\/jtd.2017.03.116","article-title":"Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases","volume":"9","author":"Kawamatawong","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/cea.12670","article-title":"Effect of roflumilast on airway remodelling in a murine model of chronic asthma","volume":"46","author":"Kim","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"p3574","DOI":"10.1124\/jpet.105.083519","article-title":"Association between comorbidities, disease severity and body mass index in COPD patients","volume":"38","author":"Knorst","year":"2011","journal-title":"Eur. Respir. J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1165\/ajrcmb.26.6.4743","article-title":"PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels","volume":"26","author":"Kohyama","year":"2002","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1378\/chest.96.6.1258","article-title":"Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease","volume":"96","author":"Laaban","year":"1989","journal-title":"Chest"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Lazaros","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2466-14-166","article-title":"The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma","volume":"14","author":"Leaker","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cophys.2017.11.004","article-title":"Cyclic AMP signaling in cardiac myocytes","volume":"1","author":"Leroy","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/nejmoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/pulp.1996.0002","article-title":"Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship","volume":"9","author":"Lipworth","year":"1996","journal-title":"Pulm. Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1124\/jpet.105.083519","article-title":"Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors","volume":"314","author":"Liu","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000095677","article-title":"Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge","volume":"74","author":"Louw","year":"2007","journal-title":"Respir."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/nejmoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1164\/rccm.200912-1869oc","article-title":"Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea","volume":"182","author":"Marin","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/s0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1164\/rccm.201607-1349oc","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.chest.2018.07.028","article-title":"Clinical approach to the therapy of asthma-COPD overlap","volume":"155","author":"Maselli","year":"2019","journal-title":"Chest"},{"key":"B80","doi-asserted-by":"publisher","first-page":"CD003002","DOI":"10.1002\/14651858.CD003002.pub3","article-title":"Drug therapy for obstructive sleep apnoea in adults","volume":"5","author":"Mason","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/thx.2004.025692","article-title":"Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells","volume":"60","author":"Mata","year":"2005","journal-title":"Thorax"},{"key":"B82","doi-asserted-by":"publisher","first-page":"P3035","DOI":"10.1159\/000095677","article-title":"Obesity in COPD, how should it be managed? - the effect of weight loss and resistance training in obese COPD patients","volume":"44","author":"McDonald","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/nejmoa1106955","article-title":"Small-airway obstruction and emphysema in chronic obstructive pulmonary disease","volume":"365","author":"McDonough","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"11A","DOI":"10.1155\/2009\/429482","article-title":"Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial","volume":"16","author":"McIvor","year":"2009","journal-title":"Can. Respir. J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnins.2011.00021","article-title":"Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions","volume":"5","author":"Medina","year":"2011","journal-title":"Front. Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","article-title":"Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials","volume":"30","author":"Metra","year":"2009","journal-title":"Eur. Heart J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/clpt.2011.266","article-title":"PDE4: a novel target in the treatment of chronic obstructive pulmonary disease","volume":"91","author":"Michalski","year":"2012","journal-title":"Clin. Pharm. Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/j.1476-5381.2012.01929.x","article-title":"Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro","volume":"166","author":"Milara","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.sleep.2014.05.012","article-title":"Weight loss from lifestyle interventions and severity of sleep apnoea: a systematic review and meta-analysis","volume":"15","author":"Mitchell","year":"2014","journal-title":"Sleep Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.resp.2018.01.008","article-title":"Inhibitors of phosphodiesterases in the treatment of cough","volume":"257","author":"Mokry","year":"2018","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.coph.2011.09.001","article-title":"PDE3 inhibition in dilated cardiomyopathy","volume":"11","author":"Movsesian","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1177\/1535370216685006","article-title":"Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice","volume":"242","author":"Murad","year":"2017","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1513\/pats.200407-037ms","article-title":"Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease","volume":"2","author":"Naeije","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"PA643","DOI":"10.1183\/13993003.congress-2016","article-title":"Effect of weight loss on COPD-associated comorbidities in obese COPD","volume":"48","author":"Negewo","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/S0091-6749(98)70036-3","article-title":"Asthma pathogenesis and allergen-induced late responses","volume":"102","author":"O\u2019Byrne","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.200807-1126OC","article-title":"START investigators group et al. severe exacerbations and decline in lung function in asthma","volume":"179","author":"O\u2019Byrne","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/nejm199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. the PROMISE study research group","volume":"325","author":"Packer","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.coph.2012.02.016","article-title":"Selective PDE inhibitors as novel treatments for respiratory diseases","volume":"12","author":"Page","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2018.06.001","article-title":"Effect of roflumilast(daxas\u00ae) in patients with symptomatic non-cystic fibrosis bronchiectasis","author":"Park","year":"2014"},{"key":"B101","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1165\/rcmb.2014-0344oc","article-title":"Inhibitors of phosphodiesterase 4, but not phosphodiesterase 3, increase \u03b22-agonist\u2013induced expression of antiinflammatory mitogen-activated protein kinase phosphatase 1 in airway smooth muscle cells","volume":"52","author":"Patel","year":"2015","journal-title":"Am. J. Respir. Cel Mol Biol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1165\/rcmb.2016-0191oc","article-title":"Roflumilast N-oxide in combination with formoterol enhances the antiinflammatory effect of dexamethasone in airway smooth muscle cells","volume":"56","author":"Patel","year":"2017","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"12","author":"Phillips","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2147\/COPD.S82509","article-title":"Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease","volume":"10","author":"Pisi","year":"2015","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/13543776.2012.696099","article-title":"TRP channels as therapeutic targets in airway disorders: a patent review","volume":"22","author":"Preti","year":"2012","journal-title":"Exp. Opin. Ther. Pat."},{"key":"B107","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s0140-6736(05)67100-0","article-title":"Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s2213-2600(18)30331-x","article-title":"Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial","volume":"6","author":"Rabe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"CD003137","DOI":"10.1002\/14651858.CD003137.pub2","article-title":"Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma","volume":"1","author":"Ram","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respir. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"150","author":"Saetta","year":"1994","journal-title":"Am. J Respir. Crit. Care Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1067\/mai.2001.118596","article-title":"The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"A1335","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of roflumilast on cough and sputum in patients with severe or very severe chronic obstructive pulmonary disease (COPD) receiving inhaled combination therapy: evaluation of the EXAcerbation of chronic pulmonary disease tool-patient reported outcomes (EXACT-PRO) subdomain scores","volume":"201","author":"Sethi","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11845-018-1738-9","article-title":"Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"187","author":"Shen","year":"2018","journal-title":"Ir. J. Med. Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1465-9921-11-26","article-title":"The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma","volume":"11","author":"Singh","year":"2010","journal-title":"Respir. Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"9","author":"Singh","year":"2019","journal-title":"Respir. Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2016.06.011","article-title":"A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients","volume":"40","author":"Singh","year":"","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1164\/rccm.201606-1179pp","article-title":"Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease","volume":"194","author":"Singh","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"A5620","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A5620","article-title":"Treatment of airway mucus hypersecretion and postnasal drip syndrome by the PDF4 inhibitor ibudilast in patients with chronic airway inflamation","volume":"181","author":"Tagaya","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1164\/ajrccm.163.2.2001038","article-title":"Relationship of epidermal growth factor receptors to goblet cell production in human bronchi","volume":"163","author":"Takeyama","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/00912700222011328","article-title":"The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-\u03b1 ex vivo","volume":"42","author":"Timmer","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"L959","DOI":"10.1152\/ajplung.00508.2007","article-title":"PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-\u03b21-stimulated fibroblasts","volume":"296","author":"Togo","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"L1068","DOI":"10.1152\/ajplung.00395.2014","article-title":"Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure","volume":"308","author":"Tyrrell","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2466-10-26","article-title":"Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice","volume":"10","author":"Udalov","year":"2010","journal-title":"BMC Pulm. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"PA693","DOI":"10.1183\/1393003.congress-2017.PA693","article-title":"Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial","volume":"50","author":"Urban","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B127","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/1753465808103499","article-title":"Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease","volume":"3","author":"Valerio","year":"2009","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaci.2005.04.023","article-title":"Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions","volume":"116","author":"Van Schalkwyk","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.rmed.2009.11.022","article-title":"Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast in Chronic Asthma (MONICA) study","volume":"104","author":"Virchow","year":"2010","journal-title":"Respir. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2017","journal-title":"J. Heart Lung Transplant."},{"key":"B131","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/COPD.S93830","article-title":"Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS\/LABA\/LAMA","volume":"11","author":"Vos","year":"2016","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B132","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/copd.s154012","article-title":"Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD","volume":"13","author":"Watz","year":"2018","journal-title":"Int. J. Chron. Obstruct Pulmon. Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/nejmoa1516385","article-title":"Indacaterol\u2013glycopyrronium versus salmeterol\u2013fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.200707-973oc","article-title":"INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1378\/chest.12-1489","article-title":"Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype","volume":"143","author":"Wedzicha","year":"2013","journal-title":"Chest"},{"key":"B136","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1513\/pats.200706-077mg","article-title":"Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease","volume":"5","author":"Weitzenblum","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"B137","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1164\/rccm.201503-0543oc","article-title":"A randomized, placebo-controlled trial of roflumilast. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease","volume":"192","author":"Wells","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1378\/chest.12-2332","article-title":"Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"144","author":"White","year":"2013","journal-title":"Chest"},{"key":"B139","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.smrv.2018.06.001","article-title":"The effect of surgical weight loss on obstructive sleep apnoea: a systematic review and meta-analysis","volume":"42","author":"Wong","year":"2018","journal-title":"Sleep Med. Rev."},{"key":"B140","doi-asserted-by":"publisher","first-page":"E1720","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus","volume":"97","author":"Wouters","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B141","doi-asserted-by":"publisher","first-page":"105950","DOI":"10.1016\/j.intimp.2019.105950","article-title":"Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials","volume":"77","author":"Yang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1183\/09031936.06.00005605","article-title":"Montelukast improves regional air-trapping due to small airways obstruction in asthma","volume":"27","author":"Zeidler","year":"2006","journal-title":"Eur. Respir. J."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2147\/dddt.s165161","article-title":"Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.13-1252","article-title":"Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study","volume":"145","author":"Zheng","year":"2014","journal-title":"Chest"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.518345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T14:01:09Z","timestamp":1628517669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.518345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":144,"alternative-id":["10.3389\/fphar.2021.518345"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.518345","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"article-number":"518345"}}